Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Docetaxel × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8 Head & Neck 5 Sarcoma 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1

Conditions

Prostatic Neoplasms 257 Urinary Bladder Neoplasms 35 Neoplasm Metastasis 27 Carcinoma, Non-Small-Cell Lung 21 Carcinoma, Transitional Cell 20 Neoplasms 19 Breast Neoplasms 18 Lung Neoplasms 13 Carcinoma, Renal Cell 12 Stomach Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 10 Ovarian Neoplasms 10 Non-Muscle Invasive Bladder Neoplasms 10 Melanoma 8 Urethral Neoplasms 6 Head and Neck Neoplasms 6 Esthesioneuroblastoma, Olfactory 6 Esophageal Neoplasms 6 Triple Negative Breast Neoplasms 5 Small Cell Lung Carcinoma 5 Salivary Gland Neoplasms 5 Prostatic Neoplasms, Castration-Resistant 5 Prostate Cancer Metastatic 5 Metastatic Castration-resistant Prostate Cancer 5 Kidney Neoplasms 5 Colorectal Neoplasms 5 Uterine Cervical Neoplasms 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Pancreatic Neoplasms 4 Pain 4

Interventions

Peripheral Blood Stem Cell Transplantation 5 Nivolumab 5 Cyclophosphamide 4 fludarabine phosphate 3 Mycophenolic Acid 3 Gemcitabine 3 Filgrastim 3 Cisplatin 3 Carboplatin 3 cabazitaxel 2 Whole-Body Irradiation 2 Therapeutics 2 Standard of Care 2 Sirolimus 2 Radiotherapy 2 Polymerase Chain Reaction 2 Mitomycin 2 Methylprednisolone 2 Methotrexate 2 Goserelin 2 Flow Cytometry 2 Cyclosporine 2 Cetuximab 2 Busulfan 2 Antilymphocyte Serum 2 thymoglobulin 1 temsirolimus 1 sargramostim 1 osunprotafib 1 motexafin gadolinium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06551324 2026-03-04

MEVPRO-1

Pfizer

Phase 3 Recruiting

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡